Username:
Password:
Forgot Password?
Remember me
Decade: 2010-2010 2000-2009 1990-1999 1980-1989 1970-1979
Year: 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000
Issues: Vol. 104 No. 12 December 15, 2009 p.1607-1764 Vol. 104 No. 11 December 1, 2009 p.1457-1606 Vol. 104 No. 10 November 16, 2009 p.1E-62E-Supplement Vol. 104 No. 10 November 15, 2009 p.1317-1456 Vol. 104 No. 9 November 1, 2009 p.1165-1316 Vol. 104 No. 8 October 15, 2009 p.1013-1164 Vol. 104 No. 7 October 1, 2009 p.873-1012 Vol. 104 No. 6 September 21, 2009 p.1D-244D-Supplement Vol. 104 No. 6 September 15, 2009 p.745-872 Vol. 104 No. 5 September 7, 2009 p.1C-64C-Supplement Vol. 104 No. 5 September 1, 2009 p.619-744 Vol. 104 No. 4 August 15, 2009 p.459-618 Vol. 104 No. 3 August 1, 2009 p.299-458 Vol. 104 No. 2 July 15, 2009 p.151-298 Vol. 104 No. 1 July 1, 2009 p.1-150 Vol. 103 No. 12 June 15, 2009 p.1629-1776 Vol. 103 No. 11 June 1, 2009 p.1481-1628 Vol. 103 No. 10 May 15, 2009 p.1333-1480 Vol. 103 No. 9 May 1, 2009 p.1183-1332 Vol. 103 No. 9 April 22, 2009 p.1B-132B-Supplement Vol. 103 No. 8 April 15, 2009 p.1045-1182 Vol. 103 No. 7 April 1, 2009 p.897-1044 Vol. 103 No. 6 March 15, 2009 p.755-896 Vol. 103 No. 5 March 1, 2009 p.577-754 Vol. 103 No. 4 February 15, 2009 p.437-576 Vol. 103 No. 3 February 2, 2009 p.1A-60A-Supplement Vol. 103 No. 3 February 1, 2009 p.295-436 Vol. 103 No. 2 January 15, 2009 p.149-294 Vol. 103 No. 1 January 1, 2009 p.1-148
Emerging Insights on Antiplatelet Therapy
Edited by Dominick J. Angiolillo MD, PhD
Publication of these proceedings were supported by educational grants provided by Daiichi Sankyo, Inc and Eli Lilly and Company.
Search Within This Issue
15 Articles:
As a sponsor accredited by the ACCME, it is the policy of the University of Wisconsin School of Medicine and Public Health to require the disclosure of the existence of any significant financial inter...
This supplement to The American Journal of Cardiology reports on the proceedings of a Scientific and Clinical Expert Panel, which was convened on November 17, 2007, in Detroit, Michigan to review curr...
Platelets play a pivotal role in atherothrombosis and therefore are primary targets of antithrombotic therapy. They release an array of agonists, such as adenosine diphosphate (ADP); adhesive molecule...
Antiplatelet therapy is an important treatment modality across the spectrum of coronary artery disease manifestations. The role of aspirin in primary prevention continues to be refined. Although monot...
This article discusses the advantages and disadvantages of methods for the measurement of platelet function. The focus is on tests that can be used to monitor antiplatelet activity in the setting of c...
Patients who have acute coronary syndromes or are undergoing percutaneous coronary intervention receive antiplatelet therapy to reduce the risk of atherothrombotic complications. Current guidelines fa...
Patients with acute coronary syndromes and patients who undergo coronary stent implantation frequently receive dual antiplatelet therapy with aspirin and a thienopyridine. A wide variability exists in...
Antiplatelet agents are the cornerstone of treatment for patients with acute coronary syndromes and patients undergoing percutaneous coronary intervention. The current “gold standard” consists of a co...
Supplement to The American Journal of Cardiology
On the Answer Sheet, please circle the letter that represents your answer for each question (you must answer 70% of the questions correctly in order to receive credit):
On the answer form, please circle the letter that represents your answer for each question (you must answer 70% of the questions correctly in order to receive credit) and MAIL or FAX to:
Did you find the information presented in the educational activity to be fair, balanced, and free of commercial bias?
